BioNTech SE Announces Positive Phase 2 Data for Influenza Vaccine
Ticker: BNTX · Form: 6-K · Filed: Jul 30, 2024 · CIK: 1776985
| Field | Detail |
|---|---|
| Company | Biontech Se (BNTX) |
| Form Type | 6-K |
| Filed Date | Jul 30, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: clinical-trial, vaccine, mRNA, influenza
TL;DR
BNTX drops positive Phase 2 flu vaccine data, could be a game-changer.
AI Summary
On July 30, 2024, BioNTech SE announced positive topline data from its Phase 2 clinical trial (EudraCT No.: 2020-002195-12; NCT04526899). The trial is evaluating a novel mRNA-based vaccine candidate for the treatment of influenza.
Why It Matters
Positive trial results could lead to a new mRNA-based influenza vaccine, potentially offering improved efficacy and a new treatment option for seasonal flu.
Risk Assessment
Risk Level: medium — Clinical trial results are promising but still require further phases and regulatory approval, with inherent risks in drug development.
Key Players & Entities
- BioNTech SE (company) — Registrant and developer of the vaccine candidate
- July 30, 2024 (date) — Date of announcement
- 2020-002195-12 (other) — EudraCT number for the clinical trial
- NCT04526899 (other) — NCT number for the clinical trial
FAQ
What specific disease is the mRNA-based vaccine candidate being evaluated for?
The mRNA-based vaccine candidate is being evaluated for the treatment of influenza.
What stage of clinical trial has BioNTech SE announced data for?
BioNTech SE announced positive topline data from the ongoing Phase 2 clinical trial.
On what date was this announcement made?
The announcement was made on July 30, 2024.
What are the identifiers for this clinical trial?
The clinical trial identifiers are EudraCT No.: 2020-002195-12 and NCT04526899.
Is BioNTech SE filing an annual report under Form 20-F or 40-F?
BioNTech SE is filing an annual report under Form 20-F.
Filing Stats: 266 words · 1 min read · ~1 pages · Grade level 13.6 · Accepted 2024-07-30 09:08:26
Filing Documents
- form6-kbnt111ph230jul2024.htm (6-K) — 15KB
- a99_1240730xprxbnt111xph2t.htm (EX-99.1) — 32KB
- image_0.jpg (GRAPHIC) — 102KB
- 0001776985-24-000064.txt ( ) — 188KB
From the Filing
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a16 OR 15d16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF JULY 2024 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant's name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20F or Form 40F Form 20F Form 40F Indicate by check mark if the registrant is submitting the Form 6K in paper as permitted by Regulation ST Rule 101(b)(1) Indicate by check mark if the registrant is submitting the Form 6K in paper as permitted by Regulation ST Rule 101(b)(7) DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K On July 30 , 2024, BioNTech SE announced positive topline data from the ongoing Phase 2 clinical trial (EudraCT No. 2020-002195-12 NCT04526899) in patients with unresectable stage III or IV melanoma whose disease had progressed following anti-PD-(L)1-containing treatment. The press release is attached hereto as Exhibit 99.1. SIGNATURE Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BioNTech SE By s Jens Holstein By s Dr. Sierk Poetting Name Jens Holstein Name Dr. Sierk Poetting Title Chief Financial Officer Title Chief Operating Officer Date July 30 , 2024 EXHIBIT INDEX Exhibit Description of Exhibit 99.1 BioNTech Announces Positive Topline Phase 2 Results for mRNA Immunotherapy Candidate BNT111 in Patients with Advanced Melanoma